Novel DOCK2-selective inhibitory peptide that suppresses B-cell line migration
Kotaro Sakamoto1, Yusuke Adachi1, Yusaku Komoike1
1Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Biochemical and Biophysical Research Communications
|January 1, 2017
Summary
Researchers developed novel peptide inhibitors targeting the DOCK2-Rac1 interaction, crucial for lymphocyte function. These peptides show potential for developing new immunosuppressive drugs for immune-related disorders.
Area of Science:
- Immunology
- Molecular Biology
- Drug Discovery
Background:
- Dedicator of cytokinesis 2 (DOCK2) is essential for lymphocyte activation and migration.
- DOCK2 interacts with Rac1 (GTPase), regulating cellular processes.
- Inhibiting the DOCK2-Rac1 protein-protein interaction (PPI) is a therapeutic strategy for immune disorders.
Purpose of the Study:
- To discover DOCK2-selective peptide inhibitors.
- To evaluate the efficacy of these peptides in inhibiting DOCK2 activity and lymphocyte migration.
Main Methods:
- Random peptide T7 phage display technology was employed to identify DOCK2-selective peptides.
- Peptides were conjugated with cell-penetrating peptides (CPPs) for intracellular delivery.
- Inhibition of lymphocyte migration was assessed using the MINO cell line.
Main Results:
- Novel DOCK2-selective peptide inhibitors were identified.
- These peptides demonstrated nanomolar inhibition of DOCK2 activity.
- One optimized peptide, R4-DCpep-2(V2W/K4R/ox)-NH2, inhibited human B lymphocyte migration at an IC50 of 120 nM.
Conclusions:
- This study reports the first DOCK2-selective peptide inhibitors.
- These peptides represent a promising new class of DOCK2-targeting immunosuppressive agents.
- The findings contribute to the development of novel therapeutics for immune-related diseases.
